Food and Drug Administration regulators turned down a request from Johnson & Johnson to expand the approved uses for Risperdal, a treatment for bipolar disorder. J&J received a not approvable letter from the FDA to use Risperdal in Alzheimer’s-related psychoses. This is after last weeks announcement that the FDA rejected J&J’s application to market Risperdal […]